Search

Your search keyword '"Geier Andreas"' showing total 1,089 results

Search Constraints

Start Over You searched for: Author "Geier Andreas" Remove constraint Author: "Geier Andreas"
1,089 results on '"Geier Andreas"'

Search Results

6. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

7. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events

9. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

13. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol

15. Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study

16. A global research priority agenda to advance public health responses to fatty liver disease

19. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

20. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

21. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling

22. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C

23. Treating hepatitis D with bulevirtide – Real-world experience from 114 patients

24. THU-269-YI Effects of semaglutide, Peptide YY3-36 and empagliflozin on metabolic dysfunctions-associated fatty steatotic liver disease in diet-induced obese rats with chronic nitric oxide synthaseinhibition

26. THU-164-YI Evaluation of four chatbots in autoimmune liver disease: a comparative analysis

29. OS-112-YI Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapybased systemic therapy

30. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

31. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

32. Effects of semaglutide, Peptide YY3-36 and empagliflozin on metabolic dysfunction associated fatty steatotic liver disease in diet-induced obese rats with chronic nitric oxide synthase-inhibition

33. Effects of antagonists of the NPY-2 receptor, semaglutide, PYY3-36, and empagliflozin on metabolic dysfunction-associated steatotic liver disease in diet-induced obese rats

34. Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case series

35. Cardio-Hepatic Interaction in Cardiac Amyloidosis

37. Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information

39. Amendment „Neue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion assoziierte steatotische Lebererkrankung) " zur S2k-Leitlinie „Nicht-alkoholische Fettlebererkrankung" (v.2.0/April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)

42. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

44. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion

45. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0

46. Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (HCC): MONTBLANC.

47. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion

48. LiverPRO for the Prediction of Significant Liver Fibrosis in Primary Care: Development, Validation, and Prognostic Evaluation of a Novel Score

49. The inhibition of YAP Signaling Prevents Chronic Biliary Fibrosis in the Abcb4-/- Model by Modulation of Hepatic Stellate Cell and Bile Duct Epithelium Cell Pathophysiology

50. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0

Catalog

Books, media, physical & digital resources